PanTera, a joint venture rooted in Belgium’s nuclear research ecosystem, industrialises the production of actinium-225, a scarce radioisotope used in targeted alpha therapy. It is building dedicated production capacity. Customers are radiopharmaceutical developers and manufacturers.
Large-scale production of actinium-225 radioisotope for targeted therapies
This profile is maintained by the Sesamers data desk. Claim it to edit details, post jobs and answer interviews.
€134,000,000
Total raised
-
Valuation
66
Employees
2022
Founded
Latest round
Equity - January 1, 2026
Equity - €134,000,000
January 1, 2026
Open roles
PanTera is not hiring through Sesamers right now.
Work here? Claim the profile and post roles.
Claim your profile